Introduction {#s1}
============

Melanoma is considered a highly immunogenic tumor [@pone.0050692-Zeuthen1]--[@pone.0050692-Kirkin2]. Strong evidence of the interaction of melanoma with the immune system has been supported by spontaneous remissions of growing melanomas [@pone.0050692-Barnetson1], presence of tumor-infiltrated lymphocytes and development of vitiligo, which is associated with improved prognosis [@pone.0050692-Kiniwa1]. An increased incidence of melanoma tumors in transplant recipients [@pone.0050692-Stoff1] and evidence of immunoevasion are also common occurrences [@pone.0050692-Gajewski1]. Immunotherapy has been one of the standard treatments in combating metastasized disease, however, the response rate remains poor [@pone.0050692-Rass1], [@pone.0050692-Sznol1]. In order to increase humoral and cell mediated immunity against melanoma, therapies that include cytokines are used particularly in the adjuvant setting. Interferon-alpha (IFNA), a type I IFN has been reproducibly shown to affect melanoma behavior in humans and despite side effects it has been associated with prolonged relapse-free survival [@pone.0050692-Garbe1]--[@pone.0050692-Kirkwood1]. A clear effect on disease free and distant metastasis free survival but not on the overall survival was observed in high risk patients [@pone.0050692-Mohr1], [@pone.0050692-Eggermont1]. Evidence suggested that the level of responsiveness to IFN treatment varies among individuals. Among the different possible causes for these inter-subject variations are the genetic polymorphisms. Associations of genetic variants in several type I *IFN* genes with different diseases, including melanoma have been reported in several studies [@pone.0050692-Yang1]--[@pone.0050692-Janssen1].

Human type I *IFN* genes are located on chromosome 9p and, with an exception of *IFN kappa*, form a cluster upstream of the *CDKN2A* and *CDKN2B* tumor-suppressor genes and the noncoding antisense RNA encoded by *CDKN2BAS*. The region is frequently mutated and deleted in a wide variety of tumors and associated with melanoma [@pone.0050692-Sini1], [@pone.0050692-Cunnington1]. In this work, we aimed at surveying an entire set of variants spanning a 342 kb region with type I *IFN* genes with focus on the cluster on chromosome 9p22. The role of genetic variants in the type I *IFN* genes was investigated for association with melanoma survival and therapy in melanoma patients recruited in Germany. The results from the investigation of these polymorphisms were additionally confirmed in an independent group of patients recruited in Spain.

Materials and Methods {#s2}
=====================

Study Population {#s2a}
----------------

The study was carried out on 752 German cutaneous melanoma patients. Survival analysis included 625 patients diagnosed at AJCC stage 0, I and II; complete data for age, gender and Breslow thickness were available for 541 patients ([Table 1](#pone-0050692-t001){ref-type="table"}). Melanoma cases were referred to the Skin Cancer Unit, German Cancer Research Center Heidelberg, at the University Hospital Mannheim. For validation purposes, 837 patients from Spain were added to the study, which included 797 patients with tumors classified with AJCC stage 0, I or II and and 725 patients had complete information for age, gender and Breslow thickness ([Table 1](#pone-0050692-t001){ref-type="table"}). Spanish melanoma patients were recruited at the Department of Dermatology, Instituto Valenciano de Oncologia, a referral skin cancer centre for the provinces of Valencia, Alicante, and Castellón, with a catchment population of ∼5 million people. Blood samples from melanoma patients were collected between 2000 and 2007 and diagnoses were confirmed by histopathology. The ethical approval for the study was granted by Ethics Commission of the Faculty of Clinical Medicine of University of Heidelberg and written informed consent was obtained from all study participants. All the patients were of European ethnicity.
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###### Characteristics of the melanoma patients from Germany and Spain.

![](pone.0050692.t001){#pone-0050692-t001-1}

                                        GERMANY        SPAIN                                                    
  ---------------------------------- ------------- ------------- ------------------ ------------- ------------- ------------------
  ***Number of patients***                752           625             541              837           710             638
  ***Gender***                                                                                                  
  **Male**                            412 (54.8%)   341 (54.6%)     301 (55.6%)      379 (45.3%)   309 (43.5%)     281 (44.0%)
  **Female**                          340 (45.2%)   284 (45.4%)     240 (44.4%)      458 (54.7%)   401 (56.5%)     357 (56.0%)
  ***Age at FD***                                                                                               
  **Median**                              55            55               55              53            52               52
  **Mean**                               54.0          54.0             54.4            51.5          51.0             50.8
  **Standard deviation**                 16.0          15.9             15.7            16.0          16.0             16.0
  ***Breslow thickness (mm)***                                                                                  
  **Median**                               −             −              1.2              --            --              1.0
  **Mean (95%CI)**                         −             −         1.8 (1.6--1.9)        --            --         1.6 (1.5--1.8)
  **Standard deviation**                   −             −              1.8              --            --              1.9
  **Range (minimum, maximum)**             −             −        14.0 (0.0, 14.0)       --            --        17.9 (0.1, 18.0)
  ***AJCC stages at FD***                                                                                       
  **0**                                10 (1.3%)     10 (1.6%)        6 (1.1%)        70 (8.4%)     70 (8.8%)        4 (0.6%)
  **I**                               400 (53.2%)   400 (64.0%)     338 (62.5%)      451 (53.9%)   451 (56.7%)     446 (69.9%)
  **II**                              215 (28.6%)   215 (34.4%)     197 (36.4%)      189 (22.6%)   189 (23.7%)     188 (29.5%)
  **III**                             111 (14.8%)       --               --          114 (13.6%)       --               --
  **IV**                               11 (1.5%)        --               --           4 (0.5%)         --               --
  **unknown**                          5 (0.7%)         \-               --           10 (1.2%)        --               --
  ***Total number of metastasis***    379 (50.4%)   257 (41.1%)     218 (40.3%)      146 (17.4%)   92 (12.9%)       87 (13.6%)
  ***Total number of deaths***        238 (31.6%)   174 (27.8%)     146 (27.0%)       77 (9.2%)     45 (6.3%)       45 (7.1%)

Selection of Polymorphisms in Interferon Gene Cluster on Chromosome 9p22 {#s2b}
------------------------------------------------------------------------

We selected 44 SNPs using tagging approach, which encompassed 15 genes and represented 299 SNPs tagged with a rˆ2≥0.8 ([Table S1](#pone.0050692.s001){ref-type="supplementary-material"}). We aimed to evaluate an entire set of variants within a 342 kb region that contained a cluster of type I interferon genes on chromosome 9p22. *IFNW1*, located 24 kb farther from *IFNA21*, and *IFNE*, located at a distance of 40 kb from *IFNA1*, defined the limits of the locus. We included SNPs within the *KLH9* gene because of its location within the type I interferon cluster ([Figure 1](#pone-0050692-g001){ref-type="fig"}). The inclusion criteria also included a minor allele frequency (MAF) of 5% or more in Caucasian population based on HapMap data (release \#28).

![Type I interferons cluster region studied on chromosome 9p22.](pone.0050692.g001){#pone-0050692-g001}

Genotyping {#s2c}
----------

Genotyping was carried out using an allelic discrimination method (Kaspar Assay from KBiosciences). PCR was carried out in 384-well format in a total volume of 4µl using 5 ng of DNA template, 0.11µl of assay mix (100 nM of two allele specific forward primers and common reverse primer, final concentration), 4µl reaction mix (Kbiosciences) and MgCl~2~. The reactions were performed using standard optimized conditions. Undetermined samples were genotyped again separately in a 96-well plate format. For quality control, ∼5% of samples were randomly selected and included as replicates.

Statistical Analysis {#s2d}
--------------------

Survival analyses were performed for the polymorphisms within the interferon genes in order to investigate the influence of the genotypes on disease free survival (DFS), time from metastasis to death (MD) and overall survival (OS). DFS was defined as the time (in years) from diagnosis of primary melanoma until the first metastasis (either regional or distant). MD survival was defined as the time from first metastasis to death or last patient contact. For MD analysis we only considered those patients who developed metastasis during the follow up time. The OS was the time from date of first diagnosis until death or last patient contact. The associations of the genotypes with DFS, MD and OS were estimated for 10 years using Kaplan-Meier methods and log-rank test was used to compare difference between the survival curves. Haplotype frequencies were inferred using the expectation-maximization algorithm (PROC HAPLOTYPE, SAS/Genetics Software). For the genotypes and inferred haplotypes associations were estimated as hazard ratio (HR) based on Cox regression, adjusted for gender, age and Breslow thickness (PROC PHREG, SAS 9.2). The analysis was carried out on data from the German and Spanish patients without metastasis at first diagnosis (AJCC stages 0, I or II) with adjustment for age, gender and Breslow thickness ([Tables S2](#pone.0050692.s002){ref-type="supplementary-material"} and [S3](#pone.0050692.s003){ref-type="supplementary-material"}). Ulceration status was not included in the multivariate analysis due to unavailability of complete data.

Determination of the Effect of Genotypes on Melanoma Therapy {#s2e}
------------------------------------------------------------

Genotype data were also analyzed after stratification of both German and Spanish melanoma patients on the basis of administered therapy; survival analyses were performed on different subgroups of patients, separately. Start time and duration of therapy were considered to explore the possible interaction between therapy and genotypes. The treatment was taken into account in statistics analysis as a time-dependent variable. The variability in treatment in terms of dosage and frequency could not be evaluated due to lack of information.

German melanoma patients included those who did not receive any therapy or those who received different kinds of therapies including chemotherapy, radiotherapy and/or immunotherapy. Within the immune-treated group there were those patients that received interferon as adjuvant therapy, and those patients that received different types of immune-treatment in stage IV as part of an chemoimmunotherapy regimen ([Figure 2](#pone-0050692-g002){ref-type="fig"} A). We analyzed data after stratification into groups, those who received interferon, alone or in combination with some other kind of treatment (chemotherapy and/or radiotherapy), and the rest of the patients that never received interferon. We called these two groups "with interferon" and "without interferon", respectively ([Figure 2](#pone-0050692-g002){ref-type="fig"} B and C). We also compared a subgroup of 84 patients that received only interferon and no other kind of treatment with the total set of the patients without therapy and those that went under different therapies without only IFN. We called these groups "with only interferon" and "without only interferon", respectively ([Figure 2](#pone-0050692-g002){ref-type="fig"} D and E).

![A, Number of melanoma patients from Germany and therapy types.\
B, "with IFN", patients that received IFN alone or combined with other treatments. C, "without IFN", patients that either did not receive any therapy or that received different kinds of therapies but never IFN. D, "with only IFN", patients that received only IFN as therapy. E, "without only IFN", patients that either did not receive any therapy or that received different kinds of therapies combined or not with IFN. IFN, interferon; C, chemotherapy; R, radiotherapy; INI, immunotherapy no IFN; NT, no treatment.](pone.0050692.g002){#pone-0050692-g002}

Spanish melanoma patient group was comprised of cases those received interferon as adjuvant treatment and those who did not receive any kind of treatment. These patients were analyzed under similar criteria of "with only interferon" and "without only interferon", with the difference being that, unlike the patients from Germany, in the "without only interferon" group, the Spanish melanoma patients received no treatment at all.

Prediction of Functional Effects of Human SNPs Located at the 5′ and 3′UTR {#s2f}
--------------------------------------------------------------------------

Prediction models were used for the role in putative miRNA-mRNA interactions of those polymorphisms that were associated with different melanoma survival parameters and were located within and near 3′UTRs of the genes. Different algorithms were used to predict the ability of the variant to affect miRNA binding sites, which included PITA (<http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html>) [@pone.0050692-Kertesz1], PolymiRTS ([Poly]{.ul}morphism in [mi]{.ul}cro[R]{.ul}NA [T]{.ul}arget [S]{.ul}ite) Database 2.0 (<http://compbio.uthsc.edu/miRSNP/search.php>) [@pone.0050692-Bao1]--[@pone.0050692-John1], and miRanda (<http://www.microrna.org/microrna/getGeneForm.do>) [@pone.0050692-John1], [@pone.0050692-Betel1]. Similarly, in order to identify putative transcription factor binding sites at sequence motifs containing melanoma survival associated SNPs, located near 5′UTRs of the genes, we used the TESS (Transcription Element Search System) web-based software tool (<http://www.cbil.upenn.edu/cgi-bin/tess>) [@pone.0050692-Schug1].

Results {#s3}
=======

Results of Genotype Analysis of Polymorphisms in Interferon Genes {#s3a}
-----------------------------------------------------------------

We genotyped 625 melanoma patients recruited in an oncology center in Germany for 44 polymorphisms located on chromosome 9p22 that were informative for 299 polymorphisms and spanned 15 type I interferon genes. Data analysis showed statistical significant association between variants alleles of three polymorphisms, rs10964859 (3′UTR of *IFNW1*), rs10964862 and rs597408, in more than one survival parameter ([Table 2](#pone-0050692-t002){ref-type="table"}). The three polymorphisms were additionally genotyped in an independent set of 797 melanoma patients recruited in Valencia, Spain, and the data confirmed the association between the rs10964859 and rs10964862 polymorphisms and different survival parameters similar to that in German patients. The association observed for the rs597408 polymorphism in German melanoma patients did not replicate in Spanish patients.
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###### Estimated 10 years survival analysis performed on the patients from Germany with first metastasis at diagnosis adjusted for age, gender and Breslow thickness.

![](pone.0050692.t002){#pone-0050692-t002-2}

                             Overall survival   Disease free progression   Metastasis to death                                                                                                                                         
  ---------------- -------- ------------------ -------------------------- --------------------- ------- --------------- ---------- ----- ----- -------- ------- --------------- ---------- ----- ----- -------- ------ --------------- ----------
  **rs1424860**       TT           385                     90                     23.40          1.00     (referent)        \-      385   141   36.60    1.00     (referent)        \-      155   100   64.50    1.00    (referent)        \-
                      TC           138                     26                     18.80          0.63    (0.40 - 1.00)   **0.05**   138   52    37.70    0.89    (0.64 - 1.24)     0.49     57    30    52.60    0.68   (0.45 - 1.03)     0.07
                      CC            8                      2                      25.00          0.94    (0.23 - 3.85)     0.94      8     3    37.50    1.04    (0.33 - 3.26)     0.95      4     3    75.00    1.36   (0.43 - 4.32)     0.60
                    TC +CC         146                     28                     19.20          0.65    (0.42 - 1.01)     0.06     146   55    37.70    0.90    (0.65 - 1.24)     0.51     61    33    54.10    0.71   (0.48 - 1.07)     0.10
  **rs10964859**      CC           232                     43                     18.50          1.00     (referent)        \-      232   72    31.00    1.00     (referent)        \-      84    51    60.70    1.00    (referent)        \-
                      CG           247                     57                     23.10          1.16    (0.77 - 1.73)     0.48     247   97    39.30    1.29    (0.94 - 1.76)     0.11     104   62    59.60    1.00   (0.68 - 1.46)     1.00
                      GG            57                     17                     29.80          1.80    (1.02 - 3.16)   **0.04**   57    26    45.60    1.51    (0.96 - 2.37)     0.07     27    20    74.10    2.01   (1.17 - 3.44)   **0.01**
                    CG +GG         304                     74                     24.30          1.27    (0.87 - 1.86)     0.22     304   123   40.50    1.33    (0.99 - 1.79)     0.06     131   82    62.60    1.14   (0.80 - 1.63)     0.46
  **rs10511694**      CC           267                     65                     24.30          1.00     (referent)        \-      267   105   39.30    1.00     (referent)        \-      114   76    66.70    1.00    (referent)        \-
                      TC           219                     43                     19.60          0.80    (0.54 - 1.19)     0.28     219   76    34.70    0.95    (0.70 - 1.29)     0.75     85    47    55.30    0.64   (0.44 - 0.92)   **0.02**
                      TT            52                     10                     19.20          0.74    (0.38 - 1.46)     0.39     52    15    28.80    0.67    (0.39 - 1.16)     0.15     17    10    58.80    0.63   (0.32 - 1.23)     0.18
                    TC +TT         271                     53                     19.60          0.79    (0.55 - 1.15)     0.22     271   91    33.60    0.89    (0.67 - 1.19)     0.43     102   57    55.90    0.64   (0.45 - 0.90)   **0.01**
  **rs2081381**       CC           197                     44                     22.30          1.00     (referent)        \-      197   75    38.10    1.00     (referent)        \-      83    50    60.20    1.00    (referent)        \-
                      CG           264                     59                     22.30          1.07    (0.72 - 1.59)     0.74     264   101   38.30    1.02    (0.75 - 1.37)     0.92     107   65    60.70    1.21   (0.83 - 1.75)     0.33
                      GG            65                     13                     20.00          1.02    (0.55 - 1.90)     0.95     65    18    27.70    0.74    (0.44 - 1.25)     0.26     24    17    70.80    1.21   (0.69 - 2.12)     0.51
                    CG +GG         329                     72                     21.90          1.06    (0.72 - 1.55)     0.77     329   119   36.20    0.96    (0.72 - 1.29)     0.79     131   82    62.60    1.21   (0.85 - 1.72)     0.30
  **rs10081742**      AA           396                     81                     20.50          1.00     (referent)        \-      396   136   34.30    1.00     (referent)        \-      150   88    58.70    1.00    (referent)        \-
                      AG           124                     35                     28.20          1.54    (1.03 - 2.31)   **0.04**   124   55    44.40    1.47    (1.07 - 2.03)   **0.02**   59    42    71.20    1.43   (0.97 - 2.10)     0.07
                      GG            7                      \-                      \-             \-          \-            \-       7     3    42.90    0.74    (0.23 - 2.38)     0.62      4    \-      \-      \-         \-            \-
                    AG +GG         131                     35                     26.70          1.31    (0.87 - 1.96)     0.19     131   58    44.30    1.40    (1.03 - 1.91)   **0.03**   63    42    66.70    1.32   (0.90 - 1.94)     0.16
  **rs10964862**      CC           231                     43                     18.60          1.00     (referent)        \-      231   69    29.90    1.00     (referent)        \-      80    47    58.80    1.00    (referent)        \-
                      CA           253                     60                     23.70          1.12    (0.75 - 1.69)     0.58     253   104   41.10    1.38    (1.01 - 1.88)   **0.04**   112   69    61.60    1.04   (0.71 - 1.52)     0.85
                      AA            49                     14                     28.60          1.67    (0.91 - 3.07)     0.10     49    23    46.90    1.63    (1.01 - 2.62)   **0.04**   24    17    70.80    1.84   (1.03 - 3.27)   **0.04**
                    CA +AA         302                     74                     24.50          1.20    (0.82 - 1.78)     0.35     302   127   42.10    1.42    (1.05 - 1.91)   **0.02**   136   86    63.20    1.14   (0.79 - 1.64)     0.50
  **rs10964863**      CC           217                     49                     22.60          1.00     (referent)        \-      217   83    38.20    1.00     (referent)        \-      93    58    62.40    1.00    (referent)        \-
                      CT           258                     55                     21.30          1.02    (0.70 - 1.51)     0.90     258   100   38.80    1.01    (0.76 - 1.36)     0.93     106   60    56.60    0.98   (0.68 - 1.41)     0.90
                      TT            49                     11                     22.40          1.15    (0.60 - 2.22)     0.68     49    10    20.40    0.53    (0.27 - 1.02)     0.06     14    12    85.70    1.58   (0.84 - 2.97)     0.15
                    CT +TT         307                     66                     21.50          1.04    (0.72 - 1.51)     0.82     307   110   35.80    0.93    (0.70 - 1.24)     0.64     120   72    60.00    1.04   (0.74 - 1.48)     0.81
  **rs10811482**      AA           319                     71                     22.30          1.00     (referent)        \-      319   109   34.20    1.00     (referent)        \-      123   77    62.60    1.00    (referent)        \-
                      AG           196                     39                     19.90          0.83    (0.56 - 1.24)     0.37     196   75    38.30    1.07    (0.79 - 1.44)     0.68     81    48    59.30    0.98   (0.68 - 1.41)     0.90
                      GG            18                     7                      38.90          2.07    (0.94 - 4.56)     0.07     18    10    55.60    1.65    (0.86 - 3.19)     0.14     10     7    70.00    1.79   (0.81 - 3.92)     0.15
                    AG +GG         214                     46                     21.50          0.92    (0.63 - 1.34)     0.66     214   85    39.70    1.11    (0.83 - 1.48)     0.47     91    55    60.40    1.04   (0.73 - 1.48)     0.83
  **rs7038852**       AA           180                     41                     22.80          1.00     (referent)        \-      180   64    35.60    1.00     (referent)        \-      70    44    62.90    1.00    (referent)        \-
                      AG           266                     54                     20.30          1.01    (0.67 - 1.52)     0.96     266   95    35.70    1.13    (0.82 - 1.55)     0.47     107   64    59.80    0.89   (0.60 - 1.30)     0.54
                      GG            77                     20                     26.00          1.45    (0.84 - 2.49)     0.18     77    34    44.20    1.74    (1.14 - 2.67)   **0.01**   35    22    62.90    1.00   (0.60 - 1.68)     1.00
                    AG +GG         343                     74                     21.60          1.10    (0.75 - 1.61)     0.64     343   129   37.60    1.23    (0.91 - 1.67)     0.17     142   86    60.60    0.91   (0.63 - 1.31)     0.62
  **rs4568676**       CC           189                     43                     22.80          1.00     (referent)        \-      189   73    38.60    1.00     (referent)        \-      79    48    60.80    1.00    (referent)        \-
                      CG           277                     59                     21.30          1.00    (0.67 - 1.48)     0.99     277   95    34.30    0.86    (0.64 - 1.17)     0.35     105   65    61.90    1.09   (0.75 - 1.58)     0.67
                      GG            66                     15                     22.70          0.91    (0.50 - 1.65)     0.76     66    26    39.40    0.90    (0.57 - 1.41)     0.64     30    19    63.30    1.27   (0.74 - 2.17)     0.39
                    CG +GG         343                     74                     21.60          0.98    (0.67 - 1.43)     0.91     343   121   35.30    0.87    (0.65 - 1.16)     0.35     135   84    62.20    1.12   (0.78 - 1.61)     0.53
  **rs2383183**       TT           437                     93                     21.30          1.00     (referent)        \-      437   160   36.60    1.00     (referent)        \-      178   108   60.70    1.00    (referent)        \-
                      TC            90                     23                     25.60          1.09    (0.68 - 1.73)     0.73     90    33    36.70    0.93    (0.63 - 1.36)     0.70     35    23    65.70    1.13   (0.71 - 1.78)     0.61
                      CC            9                      2                      22.20          0.77    (0.19 - 3.14)     0.72      9     3    33.30    0.88    (0.28 - 2.77)     0.83      3     2    66.70    0.80   (0.19 - 3.27)     0.75
                    TC +CC          99                     25                     25.30          1.05    (0.67 - 1.65)     0.83     99    36    36.40    0.92    (0.64 - 1.33)     0.67     38    25    65.80    1.09   (0.70 - 1.69)     0.70
  **rs10119910**      AA           329                     72                     21.90          1.00     (referent)        \-      329   122   37.10    1.00     (referent)        \-      134   82    61.20    1.00    (referent)        \-
                      AT           180                     40                     22.20          0.95    (0.64 - 1.39)     0.78     180   65    36.10    0.95    (0.71 - 1.29)     0.76     73    44    60.30    0.84   (0.58 - 1.22)     0.37
                      TT            19                     4                      21.10          0.88    (0.32 - 2.40)     0.80     19     5    26.30    0.63    (0.26 - 1.55)     0.32      5     3    60.00    0.96   (0.30 - 3.08)     0.95
                    AT +TT         199                     44                     22.10          0.94    (0.64 - 1.37)     0.74     199   70    35.20    0.92    (0.69 - 1.24)     0.59     78    47    60.30    0.85   (0.59 - 1.22)     0.38
  **rs10964912**      AA           292                     63                     21.60          1.00     (referent)        \-      292   103   35.30    1.00     (referent)        \-      111   68    61.30    1.00    (referent)        \-
                      AC           213                     50                     23.50          1.16    (0.80 - 1.69)     0.43     213   82    38.50    1.21    (0.90 - 1.62)     0.20     92    56    60.90    0.97   (0.68 - 1.39)     0.88
                      CC            30                     5                      16.70          0.59    (0.23 - 1.50)     0.27     30    10    33.30    0.64    (0.33 - 1.23)     0.18     11     8    72.70    1.78   (0.84 - 3.77)     0.14
                    AC +CC         243                     55                     22.60          1.07    (0.75 - 1.54)     0.71     243   92    37.90    1.10    (0.83 - 1.46)     0.51     103   64    62.10    1.03   (0.73 - 1.46)     0.86
  **rs13340713**      CC           495                    109                     22.00          1.00     (referent)        \-      495   181   36.60    1.00     (referent)        \-      198   122   61.60    1.00    (referent)        \-
                      CG            39                     8                      20.50          0.81    (0.39 - 1.68)     0.58     39    14    35.90    0.88    (0.51 - 1.52)     0.64     17    10    58.80    0.89   (0.46 - 1.70)     0.72
                    CG +GG          39                     8                      20.50          0.81    (0.39 - 1.68)     0.58     39    14    35.90    0.88    (0.51 - 1.52)     0.64     17    10    58.80    0.89   (0.46 - 1.70)     0.72
  **rs1330320**       TT           197                     43                     21.80          1.00     (referent)        \-      197   71    36.00    1.00     (referent)        \-      76    47    61.80    1.00    (referent)        \-
                      TC           249                     56                     22.50          0.87    (0.58 - 1.31)     0.51     249   96    38.60    1.01    (0.74 - 1.38)     0.94     107   66    61.70    0.92   (0.63 - 1.35)     0.68
                      CC            85                     18                     21.20          0.89    (0.51 - 1.54)     0.67     85    28    32.90    0.88    (0.57 - 1.37)     0.57     32    19    59.40    0.88   (0.51 - 1.51)     0.64
                    TC +CC         334                     74                     22.20          0.88    (0.60 - 1.28)     0.49     334   124   37.10    0.98    (0.73 - 1.31)     0.88     139   85    61.20    0.91   (0.63 - 1.31)     0.62
  **rs10757212**      GG           333                     72                     21.60          1.00     (referent)        \-      333   122   36.60    1.00     (referent)        \-      134   83    61.90    1.00    (referent)        \-
                      GA           184                     42                     22.80          1.01    (0.69 - 1.48)     0.97     184   70    38.00    1.04    (0.77 - 1.40)     0.80     78    48    61.50    0.88   (0.61 - 1.27)     0.51
                      AA            18                     3                      16.70          0.70    (0.22 - 2.22)     0.54     18     4    22.20    0.55    (0.20 - 1.48)     0.24      4     2    50.00    0.73   (0.18 - 3.00)     0.66
                    GA +AA         202                     45                     22.30          0.98    (0.67 - 1.42)     0.91     202   74    36.60    0.99    (0.74 - 1.32)     0.95     82    50    61.00    0.87   (0.61 - 1.25)     0.46
  **rs7031048**       AA           362                     79                     21.80          1.00     (referent)        \-      362   135   37.30    1.00     (referent)        \-      149   92    61.70    1.00    (referent)        \-
                      AG           163                     36                     22.10          0.97    (0.65 - 1.43)     0.86     163   57    35.00    0.89    (0.66 - 1.22)     0.48     63    39    61.90    0.91   (0.62 - 1.34)     0.64
                      GG            13                     3                      23.10          1.06    (0.33 - 3.38)     0.92     13     4    30.80    0.87    (0.32 - 2.38)     0.79      4     2    50.00    0.74   (0.18 - 3.04)     0.68
                    AG +GG         176                     39                     22.20          0.97    (0.66 - 1.43)     0.89     176   61    34.70    0.89    (0.66 - 1.21)     0.47     67    41    61.20    0.90   (0.62 - 1.31)     0.59
  **rs3758236**       TT           363                     79                     21.80          1.00     (referent)        \-      363   135   37.20    1.00     (referent)        \-      150   93    62.00    1.00    (referent)        \-
                      TA           158                     36                     22.80          1.03    (0.69 - 1.53)     0.89     158   55    34.80    0.93    (0.68 - 1.27)     0.65     60    38    63.30    0.93   (0.63 - 1.37)     0.71
                      AA            11                     2                      18.20          0.75    (0.18 - 3.05)     0.68     11     4    36.40    0.99    (0.36 - 2.69)     0.99      4     2    50.00    0.75   (0.18 - 3.07)     0.69
                    TA +AA         169                     38                     22.50          1.01    (0.68 - 1.49)     0.97     169   59    34.90    0.93    (0.69 - 1.27)     0.66     64    40    62.50    0.91   (0.63 - 1.34)     0.65
  **rs913931**        AA           405                     89                     22.00          1.00     (referent)        \-      405   154   38.00    1.00     (referent)        \-      171   105   61.40    1.00    (referent)        \-
                      AG           112                     26                     23.20          1.06    (0.68 - 1.64)     0.80     112   35    31.30    0.73    (0.51 - 1.06)     0.10     38    25    65.80    1.23   (0.79 - 1.90)     0.36
                      GG            8                      2                      25.00          1.62    (0.40 - 6.62)     0.50      8     4    50.00    2.11    (0.78 - 5.71)     0.14      4     2    50.00    0.88   (0.21 - 3.62)     0.86
                    AG +GG         120                     28                     23.30          1.09    (0.71 - 1.66)     0.71     120   39    32.50    0.79    (0.55 - 1.12)     0.19     42    27    64.30    1.19   (0.78 - 1.83)     0.42
  **rs597408**        AA           466                    101                     21.70          1.00     (referent)        \-      466   169   36.30    1.00     (referent)        \-      185   115   62.20    1.00    (referent)        \-
                      AG            50                     9                      18.00          0.89    (0.45 - 1.77)     0.75     50    17    34.00    0.95    (0.57 - 1.56)     0.83     21    10    47.60    0.87   (0.46 - 1.67)     0.68
                      GG            14                     7                      50.00          2.75    (1.26 - 6.00)   **0.01**   14     8    57.10    2.16    (1.05 - 4.43)   **0.04**    8     7    87.50    1.79   (0.82 - 3.93)     0.15
                    AG +GG          64                     16                     25.00          1.27    (0.75 - 2.15)     0.38     64    25    39.10    1.16    (0.76 - 1.76)     0.50     29    17    58.60    1.10   (0.66 - 1.84)     0.71
  **rs10448208**      GG           426                     94                     22.10          1.00     (referent)        \-      426   160   37.60    1.00     (referent)        \-      176   106   60.20    1.00    (referent)        \-
                      GA            92                     22                     23.90          0.95    (0.59 - 1.51)     0.81     92    32    34.80    0.78    (0.53 - 1.14)     0.20      1    \-      \-      \-         \-            \-
                      AA            4                      \-                      \-             \-          \-            \-       4     1    25.00    1.04    (0.15 - 7.48)     0.97     36    25    69.40    1.09   (0.70 - 1.70)     0.70
                    GA +AA          96                     22                     22.90          0.93    (0.58 - 1.48)     0.75     96    33    34.40    0.78    (0.54 - 1.14)     0.20     37    25    66.70    1.09   (0.70 - 1.70)     0.70
  **rs647167**        TT           382                     85                     22.30          1.00     (referent)        \-      382   146   38.20    1.00     (referent)        \-      162   101   62.30    1.00    (referent)        \-
                      TG           146                     32                     21.90          0.90    (0.60 - 1.36)     0.63     146   48    32.90    0.85    (0.61 - 1.18)     0.33     52    31    59.60    0.74   (0.49 - 1.12)     0.16
                      GG            7                      \-                      \-             \-          \-            \-       7     1    14.30    0.46    (0.06 - 3.32)     0.45      1    \-      \-      \-         \-            \-
                    TG +GG         153                     32                     20.90          0.87    (0.58 - 1.31)     0.51     153   49    32.00    0.83    (0.60 - 1.16)     0.28     53    31    58.50    0.72   (0.48 - 1.09)     0.12
  **rs615544**        CC           413                     93                     22.50          1.00     (referent)        \-      413   157   38.00    1.00     (referent)        \-      175   109   62.30    1.00    (referent)        \-
                      CA           109                     25                     22.90          0.90    (0.58 - 1.42)     0.66     109   37    33.90    0.88    (0.61 - 1.26)     0.48     39    24    61.50    0.79   (0.50 - 1.24)     0.31
                      AA            5                      \-                      \-             \-          \-           1.00      5     1    20.00    0.74    (0.10 - 5.27)     0.76      1    \-      \-      \-         \-            \-
                    CA +AA         114                     25                     21.90          0.87    (0.56 - 1.37)     0.55     114   38    33.30    0.87    (0.61 - 1.25)     0.46     40    24    60.00    0.76   (0.49 - 1.20)     0.24
  **rs10120977**      AA           329                     72                     21.90          1.00     (referent)        \-      329   119   36.20    1.00     (referent)        \-      127   77    60.60    1.00    (referent)        \-
                      AG           187                     43                     23.00          1.12    (0.77 - 1.65)     0.55     187   71    38.00    1.06    (0.79 - 1.43)     0.68     82    53    64.60    1.20   (0.84 - 1.72)     0.31
                      GG            21                     3                      14.30          0.83    (0.26 - 2.64)     0.75     21     5    23.80    0.72    (0.29 - 1.78)     0.48      6     2    33.30    0.78   (0.19 - 3.19)     0.73
                    AG +GG         208                     46                     22.10          1.10    (0.76 - 1.60)     0.62     208   76    36.50    1.03    (0.77 - 1.38)     0.83     88    55    62.50    1.18   (0.83 - 1.67)     0.36
  **rs632941**        GG           272                     59                     21.70          1.00     (referent)        \-      272   102   37.50    1.00     (referent)        \-      114   69    60.50    1.00    (referent)        \-
                      GA           238                     56                     23.50          0.96    (0.67 - 1.39)     0.84     238   90    37.80    0.93    (0.70 - 1.24)     0.63     98    63    64.30    0.90   (0.63 - 1.27)     0.55
                      AA            28                     3                      10.70          0.48    (0.15 - 1.54)     0.22     28     4    14.30    0.35    (0.13 - 0.94)   **0.04**    4     1    25.00    0.48   (0.07 - 3.49)     0.47
                    GA +AA         266                     59                     22.20          0.92    (0.64 - 1.32)     0.64     266   94    35.30    0.87    (0.66 - 1.15)     0.34     102   64    62.70    0.88   (0.62 - 1.25)     0.49
  **rs1224391**       CC           203                     45                     22.20          1.00     (referent)        \-      203   68    33.50    1.00     (referent)        \-      74    49    66.20    1.00    (referent)        \-
                      TC           256                     52                     20.30          0.80    (0.53 - 1.21)     0.29     256   98    38.30    1.17    (0.86 - 1.60)     0.32     110   62    56.40    0.77   (0.53 - 1.13)     0.18
                      TT            70                     20                     28.60          1.27    (0.75 - 2.16)     0.37     70    29    41.40    1.47    (0.95 - 2.27)     0.09     31    21    67.70    1.03   (0.62 - 1.73)     0.90
                    TC +TT         326                     72                     22.10          0.90    (0.62 - 1.32)     0.59     326   127   39.00    1.23    (0.92 - 1.66)     0.17     141   83    58.90    0.83   (0.58 - 1.19)     0.30
  **rs4978113**       TT           339                     72                     21.20          1.00     (referent)        \-      339   129   38.10    1.00     (referent)        \-      143   86    60.10    1.00    (referent)        \-
                      TC           179                     42                     23.50          0.98    (0.66 - 1.44)     0.90     179   62    34.60    0.83    (0.61 - 1.13)     0.24     68    44    64.70    0.98   (0.68 - 1.42)     0.93
                      CC            11                     1                      9.10           0.37    (0.05 - 2.67)     0.32     11     1     9.10    0.22    (0.03 - 1.60)     0.14      1    \-      \-      \-         \-            \-
                    TC +CC         190                     43                     22.60          0.94    (0.64 - 1.38)     0.75     190   63    33.20    0.80    (0.59 - 1.08)     0.14     69    44    63.80    0.96   (0.67 - 1.39)     0.83
  **rs1330322**       AA           177                     40                     22.60          1.00     (referent)        \-      177   70    39.50    1.00     (referent)        \-      75    44    58.70    1.00    (referent)        \-
                      AG           259                     57                     22.00          0.88    (0.58 - 1.33)     0.53     259   96    37.10    0.80    (0.58 - 1.10)     0.16     107   69    64.50    1.17   (0.80 - 1.72)     0.42
                      GG           102                     21                     20.60          0.93    (0.55 - 1.58)     0.79     102   30    29.40    0.71    (0.46 - 1.08)     0.11     34    20    58.80    1.02   (0.60 - 1.74)     0.93
                    AG +GG         361                     78                     21.60          0.89    (0.61 - 1.31)     0.56     361   126   34.90    0.77    (0.57 - 1.04)     0.09     141   89    63.10    1.13   (0.79 - 1.63)     0.51
  **rs7025006**       GG           156                     40                     25.60          1.00     (referent)        \-      156   61    39.10    1.00     (referent)        \-      64    40    62.50    1.00    (referent)        \-
                      GA           273                     54                     19.80          0.68    (0.45 - 1.03)     0.07     273   95    34.80    0.75    (0.54 - 1.04)     0.09     107   68    63.60    1.19   (0.80 - 1.76)     0.39
                      AA           103                     23                     22.30          0.84    (0.50 - 1.40)     0.50     103   37    35.90    0.83    (0.55 - 1.25)     0.38     42    24    57.10    0.92   (0.55 - 1.55)     0.77
                    GA +AA         376                     77                     20.50          0.72    (0.49 - 1.06)     0.10     376   132   35.10    0.77    (0.57 - 1.05)     0.10     149   92    61.70    1.11   (0.76 - 1.61)     0.60
  **rs2104880**       CC           479                    111                     23.20          1.00     (referent)        \-      479   179   37.40    1.00     (referent)        \-      198   125   63.10    1.00    (referent)        \-
                      CT            50                     7                      14.00          0.55    (0.25 - 1.17)     0.12     50    16    32.00    0.79    (0.47 - 1.32)     0.37     17     8    47.10    0.69   (0.34 - 1.42)     0.32
                      TT            1                      \-                      \-             \-          \-            \-       1     1    100.00   6.16    (0.82 - 46.1)     0.08      1    \-      \-      \-         \-            \-
                    CT +TT          51                     7                      13.70          0.55    (0.25 - 1.17)     0.12     51    17    33.30    0.83    (0.50 - 1.37)     0.47     18     8    44.40    0.69   (0.34 - 1.42)     0.32
  **rs1332179**       TT           428                     99                     23.10          1.00     (referent)        \-      428   160   37.40    1.00     (referent)        \-      177   113   63.80    1.00    (referent)        \-
                      TC           104                     19                     18.30          0.71    (0.43 - 1.16)     0.17     104   34    32.70    0.81    (0.56 - 1.17)     0.26      1    \-      \-      \-         \-            \-
                      CC            5                      \-                      \-             \-          \-            \-       5     1    20.00    0.68    (0.10 - 4.90)     0.70     37    20    54.10    0.77   (0.48 - 1.23)     0.27
                    TC +CC         109                     19                     17.40          0.69    (0.42 - 1.13)     0.14     109   35    32.10    0.80    (0.56 - 1.16)     0.25     38    20    52.60    0.77   (0.48 - 1.23)     0.27
  **rs1591032**       AA           352                     81                     23.00          1.00     (referent)        \-      352   130   36.90    1.00     (referent)        \-      145   92    63.40    1.00    (referent)        \-
                      AG           167                     32                     19.20          0.78    (0.52 - 1.18)     0.24     167   59    35.30    0.90    (0.66 - 1.23)     0.52     64    36    56.30    0.75   (0.51 - 1.11)     0.15
                      GG            11                     3                      27.30          1.34    (0.42 - 4.29)     0.63     11     4    36.40    1.25    (0.46 - 3.40)     0.66      4     3    75.00    1.00   (0.31 - 3.19)      \-
                    AG +GG         178                     35                     19.70          0.81    (0.54 - 1.21)     0.30     178   63    35.40    0.92    (0.68 - 1.24)     0.59     68    39    57.40    0.77   (0.53 - 1.12)     0.17
  **rs7871767**       GG           357                     78                     21.80          1.00     (referent)        \-      357   132   37.00    1.00     (referent)        \-      147   89    60.50    1.00    (referent)        \-
                      GA           143                     31                     21.70          0.92    (0.60 - 1.39)     0.69     143   49    34.30    0.84    (0.60 - 1.17)     0.30     51    34    66.70    1.08   (0.73 - 1.61)     0.70
                      AA            8                      \-                      \-             \-          \-            \-       8     2    25.00    0.77    (0.19 - 3.11)     0.71      2    \-      \-      \-         \-            \-
                    GA +AA         151                     31                     20.50          0.88    (0.58 - 1.33)     0.55     151   51    33.80    0.84    (0.60 - 1.16)     0.28     53    34    64.20    1.05   (0.71 - 1.57)     0.80
  **rs7043990**       TT           409                     96                     23.50          1.00     (referent)        \-      409   152   37.20    1.00     (referent)        \-      169   110   65.10    1.00    (referent)        \-
                      TC           118                     22                     18.60          0.83    (0.52 - 1.33)     0.44     118   42    35.60    1.00    (0.71 - 1.41)     0.99     45    23    51.10    0.63   (0.40 - 1.00)   **0.05**
                      CC            3                      \-                      \-             \-          \-            \-       3     1    33.30    1.10    (0.15 - 7.93)     0.92      1    \-      \-      \-         \-            \-
                    TC +CC         121                     22                     18.70          0.81    (0.51 - 1.29)     0.37     121   43    35.50    1.00    (0.71 - 1.41)     0.98     46    23    50.00    0.61   (0.39 - 0.96)   **0.03**
  **rs12337364**      CC           446                    105                     23.50          1.00     (referent)        \-      446   165   37.00    1.00     (referent)        \-      182   118   64.80    1.00    (referent)        \-
                      CT            81                     13                     16.00          0.77    (0.43 - 1.38)     0.39     81    30    37.00    1.14    (0.77 - 1.69)     0.52     33    15    45.50    0.65   (0.38 - 1.11)     0.11
                      TT            2                      \-                      \-             \-          \-            \-       2    \-      \-      \-          \-            \-      \-    \-      \-      \-         \-            \-
                    CT +TT          83                     13                     15.70          0.76    (0.42 - 1.36)     0.35     83    30    36.10    1.11    (0.75 - 1.64)     0.61     33    15    45.50    0.65   (0.38 - 1.11)     0.11
  **rs1332190**       TT           266                     62                     23.30          1.00     (referent)        \-      266   95    35.70    1.00     (referent)        \-      107   69    64.50    1.00    (referent)        \-
                      TC           227                     50                     22.00          0.86    (0.59 - 1.25)     0.42     227   89    39.20    1.02    (0.76 - 1.36)     0.92     97    59    60.80    0.84   (0.59 - 1.19)     0.33
                      CC            45                     6                      13.30          0.50    (0.22 - 1.18)     0.11     45    12    26.70    0.69    (0.38 - 1.27)     0.23     12     5    41.70    0.56   (0.22 - 1.39)     0.21
                    TC +CC         272                     56                     20.60          0.80    (0.56 - 1.15)     0.22     272   101   37.10    0.96    (0.73 - 1.27)     0.78     109   64    58.70    0.81   (0.57 - 1.13)     0.22
  **rs7864960**       GG           131                     36                     27.50          1.00     (referent)        \-      131   46    35.10    1.00     (referent)        \-      51    32    62.70    1.00    (referent)        \-
                      GA           274                     53                     19.30          0.58    (0.38 - 0.91)   **0.02**   274   101   36.90    0.89    (0.62 - 1.27)     0.52     113   66    58.40    0.99   (0.65 - 1.52)     0.96
                      AA           126                     27                     21.40          0.70    (0.42 - 1.15)     0.16     126   46    36.50    0.93    (0.61 - 1.39)     0.71     49    33    67.30    1.05   (0.64 - 1.72)     0.85
                    GA +AA         400                     80                     20.00          0.62    (0.42 - 0.93)   **0.02**   400   147   36.80    0.90    (0.65 - 1.26)     0.55     162   99    61.10    1.01   (0.67 - 1.51)     0.97
  **rs6475535**       CC           356                     77                     21.60          1.00     (referent)        \-      356   132   37.10    1.00     (referent)        \-      146   87    59.60    1.00    (referent)        \-
                      CG           168                     40                     23.80          1.00    (0.68 - 1.47)     1.00     168   62    36.90    0.92    (0.68 - 1.25)     0.62     68    45    66.20    1.05   (0.73 - 1.52)     0.79
                      GG            7                      1                      14.30          0.50    (0.07 - 3.59)     0.49      7     2    28.60    0.58    (0.14 - 2.34)     0.44      2     1    50.00    0.80   (0.11 - 5.77)     0.82
                    CG +GG         175                     41                     23.40          0.98    (0.67 - 1.43)     0.90     175   64    36.60    0.91    (0.67 - 1.23)     0.53     70    46    65.70    1.04   (0.73 - 1.50)     0.82
  **rs10491569**      CC           266                     65                     24.40          1.00     (referent)        \-      266   96    36.10    1.00     (referent)        \-      103   67    65.00    1.00    (referent)        \-
                      CT           221                     42                     19.00          0.80    (0.54 - 1.18)     0.26     221   83    37.60    1.03    (0.77 - 1.39)     0.83     94    52    55.30    0.96   (0.66 - 1.40)     0.83
                      TT            41                     11                     26.80          1.12    (0.59 - 2.12)     0.74     41    15    36.60    0.91    (0.53 - 1.57)     0.73     17    14    82.40    1.51   (0.84 - 2.70)     0.17
                    CT +TT         262                     53                     20.20          0.85    (0.59 - 1.22)     0.38     262   98    37.40    1.01    (0.76 - 1.34)     0.94     111   66    59.50    1.05   (0.74 - 1.49)     0.80
  **rs1888888**       GG           472                    100                     21.20          1.00     (referent)        \-      472   171   36.20    1.00     (referent)        \-      186   114   61.30    1.00    (referent)        \-
                      GA            62                     17                     27.40          1.39    (0.83 - 2.34)     0.21     62    22    35.50    1.02    (0.65 - 1.59)     0.95     27    18    66.70    1.39   (0.84 - 2.30)     0.19
                      AA            1                      1                     100.00          20.79   (2.79 - 155 )      \-       1     1    100.00   10.07   (1.39 - 73.2)   **0.02**    1     1    100.00   4.25   (0.58 - 31.4)     0.16
                    GA +AA          63                     17                     27.00          1.47    (0.88 - 2.44)     0.14     63    23    36.50    1.06    (0.68 - 1.64)     0.80     28    18    64.30    1.44   (0.88 - 2.36)     0.14
  **rs1412395**       AA           181                     40                     22.10          1.00     (referent)        \-      181   68    37.60    1.00     (referent)        \-      75    49    65.30    1.00    (referent)        \-
                      AG           266                     53                     19.90          1.00    (0.66 - 1.51)     1.00     266   92    34.60    1.05    (0.76 - 1.43)     0.78     102   58    56.90    0.94   (0.64 - 1.38)     0.76
                      GG            80                     22                     27.50          1.12    (0.66 - 1.88)     0.68     80    29    36.30    0.97    (0.63 - 1.50)     0.89     32    23    71.90    1.09   (0.66 - 1.81)     0.73
                    AG +GG         346                     75                     21.70          1.03    (0.70 - 1.52)     0.88     346   121   35.00    1.03    (0.76 - 1.38)     0.87     134   81    60.40    0.98   (0.68 - 1.41)     0.91
  **rs2383192**       TT           132                     28                     21.20          1.00     (referent)        \-      132   53    40.20    1.00     (referent)        \-      58    36    62.10    1.00    (referent)        \-
                      TC           284                     59                     20.80          1.08    (0.69 - 1.70)     0.74     284   99    34.90    0.93    (0.66 - 1.31)     0.68     110   64    58.20    1.03   (0.68 - 1.55)     0.90
                      CC           106                     28                     26.40          1.07    (0.63 - 1.82)     0.80     106   39    36.80    0.85    (0.56 - 1.29)     0.45     43    30    69.80    1.09   (0.66 - 1.78)     0.74
                    TC +CC         390                     87                     22.30          1.08    (0.70 - 1.66)     0.73     390   138   35.40    0.91    (0.66 - 1.25)     0.55     153   94    61.40    1.05   (0.71 - 1.54)     0.82
  **rs1125488**       AA           469                     99                     21.10          1.00     (referent)        \-      469   171   36.50    1.00     (referent)        \-      188   112   59.60    1.00    (referent)        \-
                      AC            64                     18                     28.10          1.16    (0.70 - 1.92)     0.57     64    25    39.10    1.03    (0.68 - 1.58)     0.88     27    20    74.10    1.29   (0.79 - 2.10)     0.30
                      CC            2                      \-                      \-             \-          \-            \-       2    \-      \-      \-          \-            \-      \-    \-      \-      \-         \-            \-
                    AC +CC          66                     18                     27.30          1.15    (0.69 - 1.91)     0.58     66    25    37.90    1.02    (0.67 - 1.56)     0.94     27    20    74.10    1.29   (0.79 - 2.10)     0.30
  **rs10811561**      AA           152                     37                     24.30          1.00     (referent)        \-      152   58    38.20    1.00     (referent)        \-      64    43    67.20    1.00    (referent)        \-
                      AG           289                     57                     19.70          0.87    (0.57 - 1.32)     0.51     289   103   35.60    1.10    (0.79 - 1.52)     0.58     112   62    55.40    0.79   (0.53 - 1.17)     0.25
                      GG            90                     23                     25.60          1.00    (0.59 - 1.69)     1.00     90    31    34.40    1.00    (0.64 - 1.56)     1.00     35    26    74.30    0.96   (0.58 - 1.56)     0.86
                    AG +GG         379                     80                     21.10          0.90    (0.61 - 1.34)     0.61     379   134   35.40    1.07    (0.78 - 1.47)     0.66     147   88    59.90    0.83   (0.58 - 1.21)     0.34

n, number of cases; M, number of metastasis; D, number of deaths; HR, hazard ratio; CI, confidence interval.

Data analysis showed that the carriers of the variant allele of the rs10964859 polymorphism were associated with a shorter time to the develop metastasis than the non-carriers (7.0 years versus 9.3 years; Kaplan-Meier survival log rank test P = 0.03; [Figure 3](#pone-0050692-g003){ref-type="fig"} A). Multivariate Cox regression showed associated HR 1.33 for DFS in the carriers (95%CI 0.99--1.74; P = 0.06; [Table S4](#pone.0050692.s004){ref-type="supplementary-material"}). The patients, homozygote for minor G-allele, had a median survival of 2.0 years from metastasis to death compared to 4.2 years for patients that were homozygote for major C-allele (data not shown). The multivariate Cox regression showed that the carriers of the homozygous GG-genotype for rs10964859 were associated with HR 2.01 (95%CI 1.17--3.44; P = 0.01; [Table S4](#pone.0050692.s004){ref-type="supplementary-material"}) for MD and OS (HR 1.80; 95%CI 1.02--3.16; P = 0.04; [Table S4](#pone.0050692.s004){ref-type="supplementary-material"}). Analysis of data after stratification for the therapy showed that GG genotype of the rs10964859 polymorphism was associated with reduced DFS (HR = 1.61, 95% CI 0.99--2.62; P = 0.05) in the group of patients who never received only IFN ([Table S5](#pone.0050692.s005){ref-type="supplementary-material"}, [Figure 2](#pone-0050692-g002){ref-type="fig"} E "without only IFN").

![Survival plot for the major genotype and carriers of the minor genotype for rs10964859 and rs10964862 for DFS in the (A) German and (B) Spanish patients.](pone.0050692.g003){#pone-0050692-g003}

The minor allele GG-genotype of rs10964859 was also associated with reduced time for MD in the group "without only IFN" (HR = 1.80, 95% CI 1.04--3.11; P = 0.04; [Table S5](#pone.0050692.s005){ref-type="supplementary-material"}, [Figure 2](#pone-0050692-g002){ref-type="fig"} E). 78% of the patients with GG genotype had died within the group "with IFN" (HR = 3.08, a 95% CI 1.48--6.40; P = 0.003; [Table S6](#pone.0050692.s006){ref-type="supplementary-material"}, [Figure 2](#pone-0050692-g002){ref-type="fig"} B) compared to 53% with the CC homozyous genotype. The effect of the minor allele GG genotype on the risk of death was higher with than without therapy based stratification.

The same group of patients with GG genotype showed association with OS (HR = 1.84, 95% CI 1.04--3.26; P = 0.04; [Table S5](#pone.0050692.s005){ref-type="supplementary-material"}). We observed that the detrimental effect of GG genotype on OS was mainly visible in the group that received either IFN therapy alone or in combination with other therapies (HR = 2.38, 95% CI 1.13--5.02; P = 0.02; [Table S6](#pone.0050692.s006){ref-type="supplementary-material"}, [Figure 2](#pone-0050692-g002){ref-type="fig"} B "with IFN"). Within that group 57% of the patients with the GG homozygous genotype had died compared to 30% with the CC homozyous genotype.

The analysis of data from Spanish melanoma patients showed that carriers of the variant G-allele of the rs10964859 polymorphism were associated with an early development of metastasis compared to non-carriers (log rank test P = 0.08). The carriers of GG-genotype showed reduced time for DFS, reduced time for MD and decreased OS, but associations were not statistically significant. Detrimental effect of the variant allele was more pronounced in the carrier patients and who never received IFN therapy (HR 1.88; 95% 0.97--3.65; P = 0.06; [Table S7](#pone.0050692.s007){ref-type="supplementary-material"}, [Figure 3](#pone-0050692-g003){ref-type="fig"} B).

The prediction analysis using PITA showed an intermediate ddG energy score for binding of hsa-mir-26a to the sequence motif containing the rs10964859 polymorphism. PolymiRTS algorithm predicted that CG nucleotide transition could influence the putative binding site of the hsa-miR-4503. It also indicated that the derived allele disrupts a conserved miRNA binding site.

The rs10964859 polymorphism was in linkage with 11 kb apart polymorphism rs10964862 with an r^2^ of 0.76. Melanoma patients with the variant A-allele of the rs10964862 polymorphism were associated with reduced time for DFS with 9.3 years versus 7.0 years (log rank test P = 0.03; [Figure 3C](#pone-0050692-g003){ref-type="fig"}) with multivariate HR 1.42 (95%CI 1.05--1.91; P = 0.02). The effect was statistically significant in heterozygote as well as homozygote carriers ([Table 3](#pone-0050692-t003){ref-type="table"}). The patients homozygous for minor allele were also associated with reduced time for MD (HR 1.84, 95%CI 1.03--3.27, P = 0.04; [Table 3](#pone-0050692-t003){ref-type="table"}). We also observed that the carriers of the minor allele of rs10964862 in the group of patients "without IFN" and "without only IFN" were associated with statistically significant increase in DFS rate ("without IFN" HR 1.52, 95%CI 1.02--2.28, P = 0.04; [Table S8](#pone.0050692.s008){ref-type="supplementary-material"}, [Figure 2](#pone-0050692-g002){ref-type="fig"} C and "without only IFN" HR 1.48 95%CI 1.06--2.06, P = 0.02; [Table S9](#pone.0050692.s009){ref-type="supplementary-material"}, [Figure 2](#pone-0050692-g002){ref-type="fig"} E). However the effect was not statistically significant in the groups of patients "with IFN" and "with only IFN". We observed in the group "without only IFN", patients homozygous for A-allele were at statistically increased risk of DFS (HR 1.78 95%CI 1.06--2.98; P = 0.03; [Table S9](#pone.0050692.s009){ref-type="supplementary-material"}). The minor allele AA genotype for rs10964862 was also statistically significantly associated with decreased MD survival only in the group "with IFN", (HR of 2.62, 95% CI, 1.19--5.73; P = 0.02; [Table S8](#pone.0050692.s008){ref-type="supplementary-material"}, [Figure 2](#pone-0050692-g002){ref-type="fig"} B). The validation of results in patients from Spain showed the association of the carriers of the variant allele for the rs10964862 polymorphism with a reduced DFS; though association after adjustment was not statistically significant (HR 1.32 95%CI 0.83--2.10; P = 0.24 [Table 3](#pone-0050692-t003){ref-type="table"})**.** The effect of variant genotypes on OS and MD was also not statistically significant. In the Spanish patients, for rs10964862 polymorphism, we observed that detrimental effect was statistically significant for the minor allele homozygous genotype for "without only IFN" patients (HR 2.52, 95%CI 1.07--5.90; P = 0.03; [Table S10](#pone.0050692.s010){ref-type="supplementary-material"}).

10.1371/journal.pone.0050692.t003

###### Variation rs10964862 for the OS, DFS and MD analysis for the patients from Germany and Spain adjusted for the covariates age, gender and Breslow thickness.
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  rs10964862         genotype   cases    n     \%     HR         CI           P
  ----------------- ---------- ------- ----- ------ ------ -------------- ----------
  **OS GERMAN**         CC       231    43    18.6   1.00    (referent)       --
                        CA       253    60    23.7   1.12   (0.75--1.69)     0.58
                        AA       49     14    28.6   1.67   (0.91--3.07)     0.10
                      CA +AA     302    74    24.5   1.20   (0.82--1.78)     0.35
  **OS SPANISH**        CC       271    13    4.8    1.00    (referent)       --
                        CA       295    20    6.8    1.39   (0.69--2.80)     0.36
                        AA       67      7    10.4   2.13   (0.85--5.35)     0.11
                      CA +AA     362    27    7.5    1.53   (0.79--2.97)     0.21
  **DFS GERMAN**        CC       231    69    29.9   1.00    (referent)       --
                        CA       253    104   41.1   1.38   (1.00--1.88)   **0.04**
                        AA       49     23    46.9   1.63   (1.01--2.62)   **0.04**
                      CA +AA     302    127   42.1   1.42   (1.05--1.91)   **0.02**
  **DFS SPANISH**       CC       271    28    10.3   1.00    (referent)       --
                        CA       295    38    12.9   1.24   (0.76--2.02)     0.39
                        AA       67     11    16.4   1.69   (0.84--3.40)     0.14
                      CA +AA     362    49    13.5   1.32   (0.83--2.10)     0.24
  **MD GERMAN**         CC       80     47    58.8   1.00    (referent)       --
                        CA       112    69    61.6   1.04   (0.71--1.52)     0.85
                        AA       24     17    70.8   1.84   (1.03--3.27)   **0.04**
                      CA +AA     136    86    63.2   1.14   (0.79--1.64)     0.50
  **MD SPANISH**        CC       31     16    51.6   1.00    (referent)       --
                        CA       44     20    45.5   1.02   (0.52--2.00)     0.97
                        AA       12      7    58.3   1.36   (0.55--3.34)     0.51
                      CA +AA     56     27    48.2   1.09   (0.58--2.06)     0.79

n, number of deaths for OS and MD analysis or number of metastases for DFS analysis.

OS, overall survival; DFS, disease free progression; MD, metastasis to death.

HR, Hazard Ratio; CI, Confidence Interval.

The patients with homozygous genotype for the variant G-allele for the rs597408 polymorphism were associated with DFS (HR 2.16, 95%CI 1.05--4.43, P = 0.04) and reduced OS (HR 2.75, 95%CI 1.26--6.00, P = 0.01; [Table S11](#pone.0050692.s011){ref-type="supplementary-material"}). After stratification, we also observed that detrimental effect was statistically significant for the minor allele genotype in the group "without only IFN" for the DFS (HR 2.09, 95%CI 1.01--4.29, P = 0.05) and OS analysis (HR 2.63, 95%CI 1.20--5.76, P = 0.02; [Table S12](#pone.0050692.s012){ref-type="supplementary-material"}). Though, results did not replicate in Spanish patients; however, the direction of the effect was similar. Due to lack of sufficient events in Spanish patients with GG-genotype, the analysis for OS and MD could not be performed ([Table S11](#pone.0050692.s011){ref-type="supplementary-material"}). We also observed other polymorphisms, rs10511694 (near gene-5 *IFNW1*), rs10081742 (7.20 kb from *5*′*IFNW1*) rs7038852 (near gene-3 *IFNA21*), rs632941, rs7043990 and rs7864960 were associated with one of the survival parameters ([Table 2](#pone-0050692-t002){ref-type="table"}).

Haplotype Analysis {#s3b}
------------------

Haplotypes were inferred for the polymorphisms genotyped located within a 26 kb region encompassing *IFNW1* and *IFNA21* on chromosome 9p22 that contained five SNPs that individually showed association with survival parameters. The analysis resulted in the inference of 40 haplotypes for the DFS and OS analysis and 31 haplotypes for the MD analysis for the polymorphisms rs10964859, rs105111694, rs2081381, rs10081742, rs10964862, rs10964863, rs10811482 and rs7038852. The most frequent haplotype taken as a reference was the one without any variant allele. GTCGACAA haplotype, found in 8.8% melanoma patients, showed an association with an increased risk MD (HR 1.94, 95%CI 1.16--3.26, P = 0.01) ([Table 4](#pone-0050692-t004){ref-type="table"}). This haplotype included the minor alleles G and A of the rs10964859 and rs10964862 polymorphisms respectively, which were individually associated with an increased risk of MD. Other haplotypes were associated with worse prognosis in the DFS, OS and MD analysis; however, those occurred with a frequency ≤0.7 in the investigated patients (data not shown).

10.1371/journal.pone.0050692.t004

###### MD haplotype analysis for the SNPs rs10964859 rs10511694 rs2081381 rs10081742 rs10964862 rs10964863 rs10811482 rs7038852 adjusted for the covariates age, gender and Breslow thickness.
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  haplotype              n     \%     HR          CI             P
  --------------------- ---- ------ ------- -------------- -------------
  **C-C-C-A-C-C-A-A**    82   19.0   1.00     reference         --
  **C-T-G-A-C-T-A-G**    70   16.2   1.42    (0.92--2.20)      0.11
  **G-T-C-A-A-C-G-A**    60   13.9   1.49    (0.94--2.36)      0.09
  **C-T-G-A-C-T-A-A**    51   11.8   1.05    (0.62--1.79)      0.86
  **G-T-C-G-A-C-A-A**    38   8.8    1.94    (1.16--3.26)    **0.01**
  **G-T-C-A-A-C-G-G**    37   8.6    1.38    (0.77--2.47)      0.28
  **C-C-C-A-C-C-A-G**    23   5.3    0.90    (0.46--1.76)      0.77
  **C-T-G-G-C-C-A-G**    10   2.3    1.07    (0.45--2.59)      0.87
  **C-T-C-G-A-C-A-G**    9    2.1    1.48    (0.60--3.63)      0.39
  **G-T-G-A-C-T-A-G**    7    1.6    1.45    (0.55--3.84)      0.45
  **C-T-G-A-C-C-A-A**    6    1.4    1.55    (0.60--4.04)      0.37
  **G-T-C-G-A-C-A-G**    6    1.4    1.09    (0.33--3.62)      0.88
  **G-T-C-A-A-C-A-A**    4    0.9    0.38    (0.08--1.77)      0.22
  **C-T-C-A-C-C-A-G**    3    0.7    0.48    (0.06--3.62)      0.47
  **C-C-G-A-C-C-A-G**    3    0.7    0.35    (0.05--2.56)      0.30
  **G-C-C-A-C-C-A-A**    3    0.7    19.56   (4.67--82.0)   **\<.0001**
  **C-T-G-A-C-C-A-G**    2    0.5     --          --            --
  **C-T-G-G-C-T-A-G**    2    0.5     --          --            --
  **C-C-C-A-C-T-A-A**    2    0.5     --          --            --
  **C-C-G-A-C-T-A-G**    2    0.5    2.09    (0.49--8.99)      0.32
  **G-T-C-A-A-T-A-A**    2    0.5    0.74    (0.10--5.54)      0.77
  **C-T-C-A-C-C-G-G**    1    0.2     --          --            --
  **C-T-C-G-A-C-G-A**    1    0.2    4.95    (0.61--39.8)      0.13
  **C-T-G-A-A-C-G-A**    1    0.2    6.57    (0.85--51.0)      0.07
  **C-T-G-G-C-C-A-A**    1    0.2     --          --            --
  **C-C-C-A-C-C-G-G**    1    0.2     --          --            --
  **C-C-C-A-C-T-A-G**    1    0.2     --          --            --
  **C-C-C-G-A-C-A-G**    1    0.2    66.78   (7.29--612 )   **0.0002**
  **C-C-G-A-C-C-A-A**    1    0.2    2.30    (0.29--18.6)      0.43
  **G-T-C-A-C-C-G-A**    1    0.2     --          --            --
  **G-T-G-G-A-T-A-G**    1    0.2     --          --            --

n = number of haplotypes in the population.

HR, Hazard Ratio; CI, Confidence Interval.

Discussion {#s4}
==========

Polymorphisms in type I IFN genes have been reported to be associated with different diseases [@pone.0050692-Wieczorek1]--[@pone.0050692-Janssen1]. In this study we observed that, of all the type I *IFN* variants evaluated, two linked polymorphisms rs10964862 and rs10964859, located at 3′UTR of *IFNW1,* were associated with detrimental effects on survival of melanoma patients. Those associations with poor survival were confirmed in an independent population. One of the haplotypes within the region that contained variant alleles of the both rs10964859 and rs10964862 polymorphisms, was associated with an increased risk of death. The prediction analysis showed that the rs10964862 variant is contained in a sequence with a potential binding site for the GATA transcription factors family, GT-IIA, NF-1 and NP-TCII and the variant allele results in loss of those sites. The rs10964862 polymorphism has been previously reported to be associated with reduced tanning ability in melanoma-prone families [@pone.0050692-Yang1].

The location of the cluster of type I *IFN* genes on chromosome 9p22 is in contiguity with a region associated with melanoma pathogenesis [@pone.0050692-Rakosy1]. In addition to the known tumor suppressor genes *CDKN2A* and *CDKN2B*, it was suggested that other genes and loci in this region may also be involved in melanoma and cutaneous nevi development [@pone.0050692-Bishop1]--[@pone.0050692-Chatzinasiou1]. An earlier report showed location of deletion breakpoints within the *IFN* gene cluster in primary leukemia cells that resulted in partial loss of the *IFN* genes on the short arm of chromosome 9p. It was suggested that, in addition to the classic two-hit tumor suppressor gene model, the loss of the *IFN* genes, when it occurs, may play an additional role in the progression of these tumors [@pone.0050692-Olopade1]. Moreover, the possibility that genetic variants in the region 9p21 exert effects through altering the expression of *CDKN2A* and/or genes in the region in addition to their own functional relevance has also been suggested [@pone.0050692-Yang1]. Variants associated with coronary artery disease, located in an enhancer interval on 9p21 locus, physically interact with *CDKN2A/B* and *MTAP* genes and with another interval downstream of *IFNA21*. Interestingly, this interval coincides with the region where we found the strongest associated variants with melanoma survival. In addition, it has been observed that the long-range interactions as well as the transcriptional regulation of the 9p21 locus were affected by IFN-γ treatment [@pone.0050692-Harismendy1]. Based on our observations, we hypothesize that the region of 26 kb encompassing *IFNW1* and *IFNA21* could be a regulatory region in chromosome 9p22, containing natural genetic variants, which might play a role in disease outcome in melanoma. The variants rs10964859 and rs10964862 or others in linkage might be regulatory genetic variants and probably those have some influence on *IFNW1* gene through disruption of miRNA or transcription binding sites.

Melanoma therapy with IFNA has shown limited clinical efficacy, however remarkable survival response has been reported for a small group of patients, who also were predisposed to autoimmunity [@pone.0050692-Gogas1], [@pone.0050692-Mellman1]. It has been suggested that the genetic background of the individuals could be partly the reason for the observed variation in the treatment response [@pone.0050692-Alexandrescu1]. Our data showed that variation in the effect of genotypes on the disease outcome was dependent on whether the patients were treated with IFNA.

In accordance with published reports, the beneficial effects of IFNA in the treatment of melanoma patients were observed at the beginning of the disease; however, with advancement of the disease, the effects of IFN treatment become less pronounced [@pone.0050692-Petrella1], [@pone.0050692-Larkin1]. IFN seems to be active in the eradication of micrometastasis and in the prevention of relapse. According to our data, melanoma patients who were carriers of the minor allele genotypes for rs10964859 and rs10964862 had an increased risk of metastasis, if they did not receive IFN therapy. However, their risk of death was augmented under treatment with IFN.

Our study shows that genetic variants in type I *IFN* genes play a role in melanoma disease and have an influence in the therapy outcome. Though it can be speculated, the effect being driven through variants in regulatory regions like 5′UTR or 3′UTR of *IFNW1* gene, the effect through some other functional linked SNP or gene beyond the region we studied cannot be ruled out. Polymorphisms in type I interferon genes that affect the biology of melanoma might be potentially used as predictors of survival and progression in the early stages of the disease. Genetic variants, which affect the efficacy of IFNA treatment, can also be useful for identification of patients for treatment. However, to achieve those levels of applications, it is imperative the findings reported in this study are confirmed further in large studies. It may, however, be pointed out that none of the associations between different polymorphisms and survival outcomes in melanoma patients remained significant after correction of for multiple hypothesis testing. Nevertheless, the observed associations between the rs10964862 and rs10964859 polymorphisms and survival parameters were uniform in two independent groups of patients.
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